Altered cerebral vascular volumes and solute transport at the blood–brain barriers of two transgenic mouse models of Alzheimer's disease

[1]  F. Calon,et al.  Brain uptake of a fluorescent vector targeting the transferrin receptor: a novel application of in situ brain perfusion. , 2014, Molecular pharmaceutics.

[2]  R. Brinton,et al.  Early Decline in Glucose Transport and Metabolism Precedes Shift to Ketogenic System in Female Aging and Alzheimer's Mouse Brain: Implication for Bioenergetic Intervention , 2013, PloS one.

[3]  P. Dederen,et al.  Microvascular cerebral blood volume changes in aging APPswe/PS1dE9 AD mouse model: a voxel-wise approach , 2013, Brain Structure and Function.

[4]  J. Rossier,et al.  Impaired neurovascular coupling in the APPxPS1 mouse model of Alzheimer's disease. , 2012, Current Alzheimer research.

[5]  Bojana Stefanovic,et al.  Amyloid-β-dependent compromise of microvascular structure and function in a model of Alzheimer's disease. , 2012, Brain : a journal of neurology.

[6]  B. Zlokovic,et al.  Hypertension Induces Brain &bgr;-Amyloid Accumulation, Cognitive Impairment, and Memory Deterioration Through Activation of Receptor for Advanced Glycation End Products in Brain Vasculature , 2012, Hypertension.

[7]  Marwan N. Sabbagh,et al.  Morphological and Pathological Evolution of the Brain Microcirculation in Aging and Alzheimer’s Disease , 2012, PloS one.

[8]  D. Llano,et al.  Characterization of 7- and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer's disease , 2012, Neurobiology of Aging.

[9]  B. Zlokovic.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders , 2011, Nature Reviews Neuroscience.

[10]  L. Fenart,et al.  [Role of the blood-brain barrier in Alzheimer's disease]. , 2011, Medecine sciences : M/S.

[11]  S. Kügler,et al.  Dendritic degeneration, neurovascular defects, and inflammation precede neuronal loss in a mouse model for tau-mediated neurodegeneration. , 2011, The American journal of pathology.

[12]  H. H. Marti,et al.  Impaired hypoxic response in senescent mouse brain , 2011, International Journal of Developmental Neuroscience.

[13]  Jan Warnking,et al.  Impaired cerebral vasoreactivity to CO2 in Alzheimer's disease using BOLD fMRI , 2011, NeuroImage.

[14]  E. Meyer,et al.  Vascular β-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAβ mice , 2011, Acta Neuropathologica.

[15]  Rachel L. Mistur,et al.  Framingham Cardiovascular Risk Profile Correlates with Impaired Hippocampal and Cortical Vasoreactivity to Hypercapnia , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[16]  A. Aliaga,et al.  Intact Memory in TGF-β1 Transgenic Mice Featuring Chronic Cerebrovascular Deficit: Recovery with Pioglitazone , 2011, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[18]  A. Miyanohara,et al.  Loss of Caveolin-1 Accelerates Neurodegeneration and Aging , 2010, PloS one.

[19]  X. Tong,et al.  Transgenic mice overexpressing APP and transforming growth factor-beta1 feature cognitive and vascular hallmarks of Alzheimer's disease. , 2010, The American journal of pathology.

[20]  F. Calon,et al.  High-fat diet aggravates amyloid-beta and tau pathologies in the 3xTg-AD mouse model , 2010, Neurobiology of Aging.

[21]  Marc Dhenain,et al.  Detection of vascular alterations by in vivo magnetic resonance angiography and histology in APP/PS1 mouse model of Alzheimer’s disease , 2010, Magnetic Resonance Materials in Physics, Biology and Medicine.

[22]  Joanna Wardlaw,et al.  Blood–brain barrier permeability in Alzheimer's disease: a case–control MRI study , 2009, Psychiatry Research: Neuroimaging.

[23]  Berislav V. Zlokovic,et al.  Neurovascular mechanisms and blood–brain barrier disorder in Alzheimer’s disease , 2009, Acta Neuropathologica.

[24]  F. LaFerla,et al.  Reduction of the cerebrovascular volume in a transgenic mouse model of Alzheimer's disease , 2009, Neuropharmacology.

[25]  Eric M. Reiman,et al.  FDG autoradiography reveals developmental and pathological effects of mutant amyloid in PDAPP transgenic mice , 2008, International Journal of Developmental Neuroscience.

[26]  I. Grundke‐Iqbal,et al.  Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer disease , 2008, FEBS letters.

[27]  H. Tanila,et al.  Amyloid beta deposition is related to decreased glucose transporter-1 levels and hippocampal atrophy in brains of aged APP/PS1 mice , 2007, Brain Research.

[28]  J. Kaye,et al.  Blood–brain barrier impairment in Alzheimer disease , 2007, Neurology.

[29]  H. Saiki,et al.  Capillary beds are decreased in Alzheimer's disease, but not in Binswanger's disease , 2007, Neuroscience Letters.

[30]  C. Anthony Hunt,et al.  Glucose transport to the brain: A systems model , 2005, Brain Research Reviews.

[31]  D. Ingram,et al.  Stereological analysis of microvascular parameters in a double transgenic model of Alzheimer's disease , 2005, Brain Research Bulletin.

[32]  J. C. Torre.  Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics , 2004, The Lancet Neurology.

[33]  D. Dickstein,et al.  Blood—Brain Barrier Permeability Precedes Senile Plaque Formation in an Alzheimer Disease Model , 2003 .

[34]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[35]  L. Bronge,et al.  Magnetic resonance imaging in dementia: a study of brain white matter changes , 2002 .

[36]  W. Staines,et al.  Immunohistochemical localization and quantification of glucose transporters in the mouse brain , 2002, Neuroscience.

[37]  R. Kalaria.  Small Vessel Disease and Alzheimer’s Dementia: Pathological Considerations , 2002, Cerebrovascular Diseases.

[38]  K. Duff,et al.  Permeability of Proteins at the Blood–Brain Barrier in the Normal Adult Mouse and Double Transgenic Mouse Model of Alzheimer's Disease , 2001, Neurobiology of Disease.

[39]  M. Breteler.  Vascular Involvement in Cognitive Decline and Dementia: Epidemiologic Evidence from the Rotterdam Study and the Rotterdam Scan Study , 2000, Annals of the New York Academy of Sciences.

[40]  L. Wahlund,et al.  Contrast‐enhanced MRI of White Matter Lesions in Patients with Blood‐Brain Barrier Dysfunction , 2000, Annals of the New York Academy of Sciences.

[41]  Christophe Rousselle,et al.  Development of an In Situ Mouse Brain Perfusion Model and its Application to mdr1a P-Glycoprotein-Deficient Mice , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[42]  W. Honer,et al.  Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease , 1994, Annals of neurology.

[43]  R N Kalaria,et al.  Reduced Glucose Transporter at the Blood‐Brain Barrier and in Cerebral Cortex in Alzheimer Disease , 1989, Journal of neurochemistry.

[44]  F. Calon,et al.  ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier. , 2012, Journal of Alzheimer's disease : JAD.

[45]  P. Hof,et al.  Age-related vascular pathology in transgenic mice expressing presenilin 1-associated familial Alzheimer's disease mutations. , 2010, The American journal of pathology.

[46]  P. Eikelenboom,et al.  Morphometric changes in the cortical microvascular network in Alzheimer's disease. , 2010, Journal of Alzheimer's disease : JAD.

[47]  V. Natarajan,et al.  Vascular endothelial barrier dysfunction mediated by amyloid-beta proteins. , 2009, Journal of Alzheimer's disease : JAD.

[48]  N. Zilka,et al.  Human truncated tau is using a different mechanism from amyloid-beta to damage the blood-brain barrier. , 2009, Journal of Alzheimer's disease : JAD.

[49]  R. Egleton,et al.  Pathophysiology of the blood-brain barrier: animal models and methods. , 2008, Current topics in developmental biology.

[50]  I. Grundke‐Iqbal,et al.  Impaired brain glucose metabolism leads to Alzheimer neurofibrillary degeneration through a decrease in tau O-GlcNAcylation. , 2006, Journal of Alzheimer's disease : JAD.

[51]  S. Hoyer.  Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications. , 2004, Advances in experimental medicine and biology.

[52]  M. Senda,et al.  Age-related changes of glutathione content, glucose transport and metabolism, and mitochondrial electron transfer function in mouse brain. , 2001, Nuclear medicine and biology.